Wegovy Novo Nordisk Pharmaceuticals Pty Ltd
Product name
Wegovy
Accepted date
Jan-2024
Active ingredients
Semaglutide
Proposed indication
Indicated to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and BMI ≥27 kg/m2.
Application type
C (new indication)
Publication date
Jan-2024